Plasmodium Immunotherapy for Advanced Malignant Solid Tumors
ConditionAdvanced Malignant Solid Tumor
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorCAS Lamvac Biotech Co., Ltd.
About this trial
The purpose of this study is: 1) to evaluate the effectiveness and extended safety of the Plasmodium immunotherapy for the advanced malignant solid tumors. 2) To explore the safe and effective course of the Plasmodium immunotherapy for the advanced malignant solid tumors. 3) To explore the possible indications of Plasmodium immunotherapy for advanced malignant solid tumors.
The treatment will last 5-10 weeks from the day of successful infection and will be terminated by antimalarial drugs.
Eligibility criteria
Qualifiers
Aged 18-70 years male or female.
Patients with advanced maligant solid tumors in lung, liver, prostate, ovary, brain, thyroid and colorectum, etc.
Patients with primary central nervous system (CNS) tumor or brain metastases from solid tumors, comply with the following standards can participate in this study: Up to the clinical trial screening period, the imageological examination provides progression-free evidence for at least 3 months, blood brain barrier has not been damaged or is already recovered from the former treatment (surgery or radiotherapy) injury, without intracranial hemorrhage or myelorrhagia history, without metastases to the brain stem, midbrain, pons, medulla oblongata or eye subsidiary organs within 10 mm area (the optic nerve and optic chiasma).
The patients have measurable tumors based on the criterion of RECIST1.1.
Disqualifiers
Nasopharyngeal cancer, head and neck tumors.
HPV positive patients with advanced malignant solid tumors in cervical, anal, vulvar, vaginal and penile.
Pancreatic cancer patients.
Small cell lung cancer patients.
Trial design
Treatments tested in this trial
- Plasmodium immunotherapy
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov